| P50 | author | Rajendra Prasad | Q90724965 |
| P2093 | author name string | Aman Kumar | |
| | Niti Kumari | |
| | Vinny Gupta | |
| P2860 | cites work | Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function | Q22009393 |
| | The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis | Q22009936 |
| | Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma | Q24337664 |
| | Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein | Q24563543 |
| | The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins | Q24564802 |
| | Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex | Q24655274 |
| | A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma | Q27728074 |
| | Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network | Q27852242 |
| | Integrated molecular analysis of clear-cell renal cell carcinoma | Q27852382 |
| | Targeting HIF-1 for cancer therapy | Q27860504 |
| | Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes | Q29615757 |
| | Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein | Q29615928 |
| | Identification of the von Hippel-Lindau disease tumor suppressor gene | Q29618644 |
| | The sonic hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growth | Q33578572 |
| | Molecular genetics of clear-cell renal cell carcinoma | Q33729097 |
| | Concurrent CD44s and STAT3 expression in human clear cell renal cellular carcinoma and its impact on survival | Q33898664 |
| | Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity | Q33925065 |
| | NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. | Q33959017 |
| | Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma | Q34077263 |
| | microRNA-21 Governs TORC1 Activation in Renal Cancer Cell Proliferation and Invasion | Q34299534 |
| | Searching for the hereditary causes of renal-cell carcinoma | Q34318015 |
| | Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling | Q34576344 |
| | Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis | Q34734132 |
| | Meta-analysis identifies NF-κB as a therapeutic target in renal cancer | Q35014835 |
| | The genetic basis of renal cell carcinoma | Q35210970 |
| | Genetic and Functional Studies Implicate HIF1α as a 14q Kidney Cancer Suppressor Gene | Q35452783 |
| | Enhanced IMP3 Expression Activates NF-кB Pathway and Promotes Renal Cell Carcinoma Progression | Q35546846 |
| | Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance | Q36105139 |
| | Targeting the HGF/Met signalling pathway in cancer. | Q36142604 |
| | Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma | Q36609752 |
| | The VHL/HIF axis in clear cell renal carcinoma | Q36872295 |
| | Actuality of Warburg's views in our understanding of renal cancer metabolism. | Q36897159 |
| | Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer | Q37234734 |
| | Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer | Q37339628 |
| | Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney | Q37349768 |
| | A study exploring critical pathways in clear cell renal cell carcinoma | Q37388562 |
| | STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells | Q37404757 |
| | 2009 update on the classification of renal epithelial tumors in adults | Q37488430 |
| | Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis | Q37632111 |
| | Targeting renal cell carcinoma with a HIF-2 antagonist. | Q37684974 |
| | Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach | Q37702516 |
| | VHL and HIF signalling in renal cell carcinogenesis | Q37708208 |
| | Molecular aspects of renal cell carcinoma: a review | Q37942072 |
| | A phase I study of cabozantinib (XL184) in patients with renal cell cancer. | Q38430335 |
| | VHL promotes immune response against renal cell carcinoma via NF-κB-dependent regulation of VCAM-1. | Q38714947 |
| | PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas | Q38852640 |
| | HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome. | Q39037287 |
| | Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors | Q39051622 |
| | Loss of PBRM1 expression is associated with renal cell carcinoma progression | Q39285387 |
| | A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas | Q40274291 |
| | Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial | Q40600188 |
| | Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. | Q40633683 |
| | Hereditary Renal-Cell Carcinoma Associated with a Chromosomal Translocation | Q41751694 |
| | The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells | Q41908755 |
| | Effects of HIF-1alpha and HIF2alpha on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 Xenografts | Q42726487 |
| | HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors | Q42819341 |
| | Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma | Q46635938 |
| | Reciprocal regulation of hypoxia-inducible factor 2α and GLI1 expression associated with the radioresistance of renal cell carcinoma | Q51018011 |
| | Loss of tumor suppressor protein PTEN during renal carcinogenesis | Q53390981 |
| | The Heidelberg classification of renal cell tumours | Q55067278 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal cell carcinoma | Q1164529 |
| P304 | page(s) | 246-254 | |
| P577 | publication date | 2017-11-13 | |
| P1433 | published in | Indian journal of clinical biochemistry | Q26853918 |
| P1476 | title | Renal Cell Carcinoma: Molecular Aspects | |
| P478 | volume | 33 | |